For the study, researchers examined data on 56 patients diagnosed with AFM between 2015-16 at 12 centers across the U.S. Researchers assessed the outcomes, adverse events and adverse reactions associated with 30 AFM patients treated with fluoxetine and 26 patients who did not receive fluoxetine.
The patients who received fluoxetine had more severe paralysis than those in the control group. They did not experience any serious adverse events after taking the medication, but ultimately demonstrated poorer long-term outcomes.
Researchers concluded fluoxetine was “not associated with improved neurologic outcomes” in these patients.
More articles on clinical leadership and infection control:
College campuses see ‘compassion fatigue’ in wake of recent mass shootings
How EDs match up to urgent care centers in Yelp reviews
5 ways hospital leaders can participate in Antibiotic Awareness Week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.